18060

    543960

    CONCORDBIO

    img img img img
    No Data Available

    Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

    CONCORD BIOTECH LIMITED Share Price Today

    CONCORD BIOTECH LIMITED is currently trading at ₹1276, up by ₹1.09 from the previous close. The stock touched an intraday high of ₹1303.70 and a low of ₹1270.60 during the latest trading session. Over the past one year, CONCORD BIOTECH LIMITED has delivered a loss of 27.15%, while the stock has gained 6.1% in the last one month.

    CONCORD BIOTECH LIMITED performance

    Today’s low Today’s high
    ₹ 1270.60 ₹ 1303.70
    ₹ 1283.60
    52 week low 52 week high
    ₹ 987.00 ₹ 1980.00
    ₹ 1283.60
    Open Price ₹ 1282.50
    Prev. Close ₹ 1274.90
    Volume (Shares) 92023.00
    Total traded value ₹ 1181.20
    Upper Circuit ₹ 1529.80
    Lower Circuit ₹ 1020.00
    info

    Investment Returns

    Over 1 Month 6.10% Over 3 Months 23.81% Over 6 Months -4.69% Over 1 Year -27.15%
    demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

    CONCORD BIOTECH LIMITED fundamentals


    • Market cap (Cr) 13,428.50
    • P/E Ratio (TTM) 50.86
    • Beta 0.89
    • Book Value / share 193.06
    • Return on equity 22.35%
    • EPS (TTM) 25.40
    • Dividend yield 0.59%
    • Net profit/quarter (Cr) 90.02
    info icon alternate text
    • Market cap (Cr) 13,432.70
    • P/E Ratio (TTM) 50.86
    • Beta 0.77
    • Book Value / share 193.06
    • Return on equity 22.35%
    • EPS (TTM) 25.40
    • Dividend yield 0.59%
    • Net profit/quarter (Cr) 90.02
    info icon alternate text

    CONCORD BIOTECH LIMITED Financials

    • Key Results
    • Key Ratios
    • Balance sheet
    • Cash Flow
    • Competition
    Open financial information
    Revenue
    Net income
    Particulars MAR 2026 (Values in Cr)
    Revenue 325.89
    Operating Expense 223.06
    Net Profit 90.02
    Net Profit Margin (%) 27.62
    Earnings Per Share (EPS) 8.60
    EBITDA 137.93
    Effective Tax Rate (%) 23.95
    Particulars DEC 2025 (Values in Cr)
    Revenue 278.13
    Operating Expense 194.65
    Net Profit 67.78
    Net Profit Margin (%) 24.36
    Earnings Per Share (EPS) 6.48
    EBITDA 109.03
    Effective Tax Rate (%) 24.92
    Particulars SEP 2025 (Values in Cr)
    Revenue 247.06
    Operating Expense 174.97
    Net Profit 62.90
    Net Profit Margin (%) 25.45
    Earnings Per Share (EPS) 6.01
    EBITDA 103.97
    Effective Tax Rate (%) 26.44
    Particulars JUN 2025 (Values in Cr)
    Revenue 203.99
    Operating Expense 160.43
    Net Profit 42.57
    Net Profit Margin (%) 20.86
    Earnings Per Share (EPS) 4.07
    EBITDA 75.08
    Effective Tax Rate (%) 25.62
    Particulars MAR 2025 (Values in Cr)
    Revenue 429.88
    Operating Expense 254.18
    Net Profit 141.94
    Net Profit Margin (%) 33.01
    Earnings Per Share (EPS) 13.57
    EBITDA 199.81
    Effective Tax Rate (%) 23.31
    Particulars MAR 2026 (Values in Cr)
    Revenue 1055.07
    Operating Expense 753.09
    Net Profit 263.27
    Net Profit Margin (%) 24.95
    Earnings Per Share (EPS) 25.17
    EBITDA 425.99
    Effective Tax Rate (%) 25.08
    Particulars MAR 2025 (Values in Cr)
    Revenue 1200.09
    Operating Expense 748.66
    Net Profit 372.96
    Net Profit Margin (%) 31.07
    Earnings Per Share (EPS) 35.65
    EBITDA 550.78
    Effective Tax Rate (%) 24.78
    Particulars MAR 2024 (Values in Cr)
    Revenue 1016.94
    Operating Expense 641.52
    Net Profit 304.73
    Net Profit Margin (%) 29.96
    Earnings Per Share (EPS) 29.13
    EBITDA 465.33
    Effective Tax Rate (%) 25.52
    Particulars MAR 2023 (Values in Cr)
    Revenue 853.17
    Operating Expense 568.42
    Net Profit 238.13
    Net Profit Margin (%) 27.91
    Earnings Per Share (EPS) 22.76
    EBITDA 378.59
    Effective Tax Rate (%) 25.59
    Particulars MAR 2022 (Values in Cr)
    Revenue 712.93
    Operating Expense 495.19
    Net Profit 178.57
    Net Profit Margin (%) 25.04
    Earnings Per Share (EPS) 187.76
    EBITDA 296.69
    Effective Tax Rate (%) 25.95
    Particulars MAR 2025 (Values in Cr)
    Book Value / Share 173.27
    ROE % 22.26
    ROCE % 29.53
    Total Debt to Total Equity 0.00
    EBITDA Margin 45.83
    Particulars MAR 2024 (Values in Cr)
    Book Value / Share 145.93
    ROE % 21.88
    ROCE % 29.05
    Total Debt to Total Equity 0.01
    EBITDA Margin 46.15
    Particulars MAR 2023 (Values in Cr)
    Book Value / Share 123.31
    ROE % 20.06
    ROCE % 26.27
    Total Debt to Total Equity 0.04
    EBITDA Margin 44.68
    Particulars MAR 2022 (Values in Cr)
    Book Value / Share 1159.99
    ROE % 16.64
    ROCE % 21.59
    Total Debt to Total Equity 0.07
    EBITDA Margin 41.20
    Particulars MAR 2021 (Values in Cr)
    Book Value / Share 1050.80
    ROE % 26.60
    ROCE % 32.83
    Total Debt to Total Equity 0.08
    EBITDA Margin 55.42
    Particulars MAR 2025 (Values in Cr)
    Book Value / Share 173.27
    ROE % 22.35
    ROCE % 29.62
    Total Debt to Total Equity 0.00
    EBITDA Margin 45.94
    Particulars MAR 2024 (Values in Cr)
    Book Value / Share 145.80
    ROE % 21.63
    ROCE % 28.81
    Total Debt to Total Equity 0.01
    EBITDA Margin 45.82
    Particulars MAR 2023 (Values in Cr)
    Book Value / Share 123.50
    ROE % 19.85
    ROCE % 26.05
    Total Debt to Total Equity 0.04
    EBITDA Margin 44.45
    Particulars MAR 2022 (Values in Cr)
    Book Value / Share 1164.13
    ROE % 16.95
    ROCE % 21.86
    Total Debt to Total Equity 0.07
    EBITDA Margin 41.71
    Particulars MAR 2021 (Values in Cr)
    Book Value / Share 1051.11
    ROE % 26.59
    ROCE % 32.82
    Total Debt to Total Equity 0.08
    EBITDA Margin 55.39
    Particulars MAR 2025 (Values in Cr)
    Cash & Short Term Investments 1.18
    Total Assets 2034.25
    Total Liabilities 2034.25
    Total Equity 1812.71
    Share Outstanding 10
    Price to Book Ratio 9.67
    Return on Assets (%) 18.26
    Return on Capital (%) 20.5
    Particulars MAR 2024 (Values in Cr)
    Cash & Short Term Investments 47.02
    Total Assets 1700.70
    Total Liabilities 1700.70
    Total Equity 1526.64
    Share Outstanding 10
    Price to Book Ratio 10.44
    Return on Assets (%) 18.11
    Return on Capital (%) 20.1
    Particulars MAR 2023 (Values in Cr)
    Cash & Short Term Investments 43.44
    Total Assets 1513.98
    Total Liabilities 1513.98
    Total Equity 1290.00
    Share Outstanding 10
    Price to Book Ratio 0.00
    Return on Assets (%) 15.85
    Return on Capital (%) 18.17
    Particulars MAR 2022 (Values in Cr)
    Cash & Short Term Investments 88.93
    Total Assets 1312.79
    Total Liabilities 1312.79
    Total Equity 1103.22
    Share Outstanding 0
    Price to Book Ratio 0.00
    Return on Assets (%) 13.32
    Return on Capital (%) 15.03
    Particulars MAR 2021 (Values in Cr)
    Cash & Short Term Investments 60.81
    Total Assets 1182.54
    Total Liabilities 1182.54
    Total Equity 999.37
    Share Outstanding 0
    Price to Book Ratio 0.00
    Return on Assets (%) 19.90
    Return on Capital (%) 22.19
    Particulars MAR 2025 (Values in Cr)
    Cash & Short Term Investments 1.18
    Total Assets 2034.18
    Total Liabilities 2034.18
    Total Equity 1812.64
    Share Outstanding 10
    Price to Book Ratio 9.67
    Return on Assets (%) 18.33
    Return on Capital (%) 20.57
    Particulars MAR 2024 (Values in Cr)
    Cash & Short Term Investments 47.02
    Total Assets 1699.31
    Total Liabilities 1699.31
    Total Equity 1525.25
    Share Outstanding 10
    Price to Book Ratio 10.44
    Return on Assets (%) 17.93
    Return on Capital (%) 19.9
    Particulars MAR 2023 (Values in Cr)
    Cash & Short Term Investments 43.44
    Total Assets 1514.64
    Total Liabilities 1514.64
    Total Equity 1291.98
    Share Outstanding 10
    Price to Book Ratio 0.00
    Return on Assets (%) 15.72
    Return on Capital (%) 18
    Particulars MAR 2022 (Values in Cr)
    Cash & Short Term Investments 88.93
    Total Assets 1313.45
    Total Liabilities 1313.45
    Total Equity 1107.16
    Share Outstanding 0
    Price to Book Ratio 0.00
    Return on Assets (%) 13.59
    Return on Capital (%) 15.29
    Particulars MAR 2021 (Values in Cr)
    Cash & Short Term Investments 60.81
    Total Assets 1182.84
    Total Liabilities 1182.84
    Total Equity 999.67
    Share Outstanding 0
    Price to Book Ratio 0.00
    Return on Assets (%) 19.89
    Return on Capital (%) 21.67
    Particulars MAR 2025 (Values in Cr)
    Net Income 494.55
    Cash from Operations 353.93
    Cash from Investing -159.98
    Cash from Financing -98.76
    Net change in Cash -14.23
    Free Cash Flow 465.10
    Particulars MAR 2024 (Values in Cr)
    Net Income 412.56
    Cash from Operations 368.81
    Cash from Investing -154.60
    Cash from Financing -99.21
    Net change in Cash 11.64
    Free Cash Flow 454.50
    Particulars MAR 2023 (Values in Cr)
    Net Income 322.01
    Cash from Operations 316.27
    Cash from Investing -157.95
    Cash from Financing -85.21
    Net change in Cash 2.83
    Free Cash Flow 461.36
    Particulars MAR 2022 (Values in Cr)
    Net Income 237.51
    Cash from Operations 268.25
    Cash from Investing -111.78
    Cash from Financing -100.16
    Net change in Cash -4.47
    Free Cash Flow 423.76
    Particulars MAR 2020 (Values in Cr)
    Net Income 213.63
    Cash from Operations 204.19
    Cash from Investing -113.92
    Cash from Financing -42.51
    Net change in Cash -1.35
    Free Cash Flow 204.19
    Particulars MAR 2025 (Values in Cr)
    Net Income 495.87
    Cash from Operations 353.93
    Cash from Investing -159.98
    Cash from Financing -98.76
    Net change in Cash -14.23
    Free Cash Flow 465.10
    Particulars MAR 2024 (Values in Cr)
    Net Income 409.19
    Cash from Operations 368.81
    Cash from Investing -154.60
    Cash from Financing -99.21
    Net change in Cash 11.64
    Free Cash Flow 454.50
    Particulars MAR 2023 (Values in Cr)
    Net Income 320.05
    Cash from Operations 316.27
    Cash from Investing -157.95
    Cash from Financing -85.21
    Net change in Cash 2.83
    Free Cash Flow 461.36
    Particulars MAR 2022 (Values in Cr)
    Net Income 241.15
    Cash from Operations 268.25
    Cash from Investing -111.78
    Cash from Financing -100.16
    Net change in Cash -4.47
    Free Cash Flow 423.76
    Particulars MAR 2021 (Values in Cr)
    Net Income 313.16
    Cash from Operations 241.98
    Cash from Investing -195.20
    Cash from Financing 31.12
    Net change in Cash 2.73
    Free Cash Flow 446.16
    Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
    AMBALAL SARABHAI ENT L 32.72 13.52 1.58 250.74 23.12 38.85
    BLISS GVS PHARMA LTD 506.15 40.69 4.49 5368.04 118.35 552.90
    CIPLA LTD 1458.45 30.95 3.42 117820.20 1165.55 1672.20
    FERMENTA BIOTECH LTD. 345.85 15.26 2.50 1017.87 256.40 399.00
    Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
    AMBALAL SARABHAI ENT L 32.72 22.88 4.21 250.74 23.12 38.85
    AMRUTANJAN HEALTH CARE LTD. 536.85 24.06 4.19 1552.07 490.00 789.95
    ASTRAZENECA PHARMA IND LT 8297.90 108.37 23.76 20744.75 7630.00 9850.00
    BLISS GVS PHARMA LTD 506.15 54.72 4.64 5368.04 118.35 552.90

    CONCORD BIOTECH LIMITED shareholding pattern

    Holding
    38.9%
    44.08%
    7.79%
    9.22%
    Name Shares Category
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)
    (%)

    News

    Left Arrow
    Right Arrow

    CONCORD BIOTECH LIMITED Technicals Summary

    • EMA & SMA
    • Resistance and Support
    • Delivery and Volume
    • Beta
    • Price Change Analysis
    1283.60 0.68 redarrow
    red-green-graph indicator
    7 Bearish
    9 Bullish
    • 5 Days 1283.00
    • 26 Days 1265.50
    • 10 Days 1289.60
    • 50 Days 1227.20
    • 12 Days 1289.40
    • 100 Days 1223.20
    • 20 Days 1277.90
    • 200 Days 1312.10
    1276.67 PIVOT
    First Support 1258.23 First Resistance 1293.33 Second Support 1241.57 Second Resistance 1311.77 Third Support 1223.13 Third Resistance 1328.43
    RSI 52.10 ADX 28.77 MACD 23.85 Williams % R -87.44 Commodity Channel Index (CCI) -52.04
    Date 2026-07-03 Week 54840.00 Same Day 38242.00 Month 126479.00
    1 Year 0.90 3 Year 0.71
    Over 1 Month
    6.10% down
    Over 1 Year
    -27.15% down
    Over 3 Months
    23.81% down
    Over 3 Years
    10.58% down
    Over 6 Months
    -4.69% down
    Over 5 Years
    0.00% down

    CONCORD BIOTECH LIMITED Corporate Actions

    Dividend date Dividend amount Dividend type Record date Instrument type
    03 Sep 2025 10.7 Final 03 Sep 2025 Equity shares
    21 Jun 2024 8.75 Final 22 Jun 2024 Equity shares
    Dividend date Dividend amount Dividend type Record date Instrument type
    03 Sep 2025 10.7 Final 03 Sep 2025 Equity shares
    21 Jun 2024 8.75 Final 22 Jun 2024 Equity shares

    Top Gainers

    Top Losers

    stock
    Trade stocks with ease

    Sign-in to trade with your demat account, or set up a new demat account for free

    Board Of Directors

    Similar stocks

    Frequently Asked Questions

    What is the Current Share Price of Concord Biotech Ltd?

    Answer Field

    Concord Biotech Ltd share price is for NSE ₹ 1,276.00 & for BSE ₹ 1,280.25 as on Jul 06 2026 03:29 PM.

    What is the Market Cap of Concord Biotech Ltd Share?

    Answer Field

    The market cap of Concord Biotech Ltd for NSE ₹ 0.00 & for BSE ₹ 0.00 as on Jul 06 2026 03:29 PM.

    What is the 52 Week High and Low of Concord Biotech Ltd?

    Answer Field

    The 52 Week High and Low of Concord Biotech Ltd for NSE is ₹ 1,980.00 and ₹ 987.00 and for BSE is ₹ 1,979.20 and ₹ 987.05.

    What is 1 year return for Concord Biotech Ltd?

    Answer Field

    The 1 year returns on the stock has been -27.15%.

    What is the P/E Ratio of Concord Biotech Ltd Share?

    Answer Field

    As on Jul 06 2026 03:29 PM the price-to-earnings (PE) ratio for Concord Biotech Ltd share is 50.86.

    What is the PB ratio of Concord Biotech Ltd Share?

    Answer Field

    As on Jul 06 2026 03:29 PM, the price-to-book (PB) ratio for Concord Biotech Ltd share is 193.06.

    How to Buy Concord Biotech Ltd Share?

    Answer Field

    You can trade in Concord Biotech Ltd shares with Bajaj Broking by opening a demat account.

    How to Buy Concord Biotech Ltd Share on Bajaj Broking App?

    Answer Field

    To buy Concord Biotech Ltd shares on the Bajaj Broking app, follow these steps:

    • Login to the Bajaj Broking App

    • Click on the Search Icon

    • Search “Concord Biotech Ltd”

    • Click on the BUY icon

    • Place a buy order specifying the desired quantity of shares.

    • Click BUY again to complete the purchase

    No results found

    close-img
    Authorise with OTP
    Enter the 4-Digit OTP sent to
    edit
    OTP expires in 00:59
    banner-icon

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |

    Open Your Free Demat Account

    Enjoy low brokerage on delivery trades

    +91

    |